ECSP109864A - Formulaciones estables de derivado de tiadiazol - Google Patents

Formulaciones estables de derivado de tiadiazol

Info

Publication number
ECSP109864A
ECSP109864A EC2010009864A ECSP109864A ECSP109864A EC SP109864 A ECSP109864 A EC SP109864A EC 2010009864 A EC2010009864 A EC 2010009864A EC SP109864 A ECSP109864 A EC SP109864A EC SP109864 A ECSP109864 A EC SP109864A
Authority
EC
Ecuador
Prior art keywords
tiadiazol
derivative
stable formulations
dimethyl
stable
Prior art date
Application number
EC2010009864A
Other languages
English (en)
Inventor
Hiroko Kusano
Dinesh Shyamdeo Mishra
Yoshikazu Tashiro
Yosuke Watanabe
Hong Zhuang
Original Assignee
Lilly Co Eli
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39735000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP109864(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Kyowa Hakko Kirin Co Ltd filed Critical Lilly Co Eli
Publication of ECSP109864A publication Critical patent/ECSP109864A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere parámetros de formulación y condiciones de manufacturación para composiciones farmacéuticas estables que comprenden N-{4-(2,2-dimetil-propionil)-(5R)-5-[(2-etilamino-etansulfonilamino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil-propionamida que minimiza la conversión quiral estable a la forma enantiomérica S menos activa.
EC2010009864A 2007-07-12 2010-01-08 Formulaciones estables de derivado de tiadiazol ECSP109864A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94926807P 2007-07-12 2007-07-12

Publications (1)

Publication Number Publication Date
ECSP109864A true ECSP109864A (es) 2010-03-31

Family

ID=39735000

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009864A ECSP109864A (es) 2007-07-12 2010-01-08 Formulaciones estables de derivado de tiadiazol

Country Status (27)

Country Link
US (1) US8222284B2 (es)
EP (1) EP2178508B1 (es)
JP (1) JP4875205B2 (es)
KR (1) KR101188036B1 (es)
CN (1) CN101730525A (es)
AR (1) AR067472A1 (es)
AU (1) AU2008275258A1 (es)
BR (1) BRPI0814039A2 (es)
CA (1) CA2694277C (es)
CL (1) CL2008001996A1 (es)
CO (1) CO6270304A2 (es)
CR (1) CR11210A (es)
DO (1) DOP2010000004A (es)
EA (1) EA016861B1 (es)
EC (1) ECSP109864A (es)
ES (1) ES2401477T3 (es)
GT (1) GT201000003A (es)
IL (1) IL202382A0 (es)
MA (1) MA31880B1 (es)
MX (1) MX2010000468A (es)
NZ (1) NZ581791A (es)
PE (1) PE20090438A1 (es)
SV (1) SV2010003449A (es)
TN (1) TN2010000015A1 (es)
TW (1) TW200918050A (es)
UA (1) UA97672C2 (es)
WO (1) WO2009009470A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459909B (zh) 2009-06-26 2014-12-10 三菱电机株式会社 制冷剂压缩机

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1847534T1 (sl) 2001-12-11 2011-10-28 Kyowa Hakko Kirin Co Ltd Tiadiazolinski derivati za zdravljenje raka
CN1774428B (zh) * 2003-04-18 2010-06-16 协和发酵麒麟株式会社 M期驱动蛋白抑制剂
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
US20080262049A1 (en) * 2005-03-22 2008-10-23 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent for Hematopoietic Tumor
KR20070113300A (ko) * 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤

Also Published As

Publication number Publication date
CA2694277A1 (en) 2009-01-15
NZ581791A (en) 2012-03-30
HK1141238A1 (en) 2010-11-05
EP2178508B1 (en) 2013-02-06
CR11210A (es) 2010-06-23
TW200918050A (en) 2009-05-01
DOP2010000004A (es) 2010-03-15
JP2010533190A (ja) 2010-10-21
ES2401477T3 (es) 2013-04-19
CO6270304A2 (es) 2011-04-20
KR101188036B1 (ko) 2012-10-05
TN2010000015A1 (en) 2011-09-26
AU2008275258A1 (en) 2009-01-15
BRPI0814039A2 (pt) 2017-10-03
SV2010003449A (es) 2010-08-10
CA2694277C (en) 2013-04-09
EA016861B1 (ru) 2012-08-30
US20110009458A1 (en) 2011-01-13
AR067472A1 (es) 2009-10-14
MX2010000468A (es) 2010-04-09
CN101730525A (zh) 2010-06-09
EP2178508A1 (en) 2010-04-28
MA31880B1 (fr) 2010-12-01
PE20090438A1 (es) 2009-04-18
JP4875205B2 (ja) 2012-02-15
EA201070136A1 (ru) 2010-06-30
IL202382A0 (en) 2010-06-30
GT201000003A (es) 2012-03-13
CL2008001996A1 (es) 2009-05-22
KR20100029827A (ko) 2010-03-17
UA97672C2 (ru) 2012-03-12
US8222284B2 (en) 2012-07-17
WO2009009470A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2011148328A3 (en) Cosmetic process for making-up and/or caring for the skin and/or the lips
ECSP066715A (es)
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2599475A3 (en) Pharmaceutical composition having desirable bioavailability
WO2011006935A3 (en) Tetrazole derivatives
NO20075111L (no) Farmasoytisk sammensetning
WO2009105969A8 (zh) 埃坡霉素类似物、其药物组合物、用途及其制备方法
WO2011023367A3 (en) Bisphosphonate-prodrugs
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2009120885A3 (en) Stabilizing lipid compositions for oral pharmaceutical agents
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006136580A3 (en) 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008098143A3 (en) Antimicrobial compounds and methods of use
ECSP109864A (es) Formulaciones estables de derivado de tiadiazol
EA201291401A1 (ru) НОВЫЕ ПРОТИВОГРИБКОВЫЕ ПРОИЗВОДНЫЕ 5,6-ДИГИДРО-4-[(ДИФТОРЭТИЛ)ФЕНИЛ]-4H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА И 4-(ДИФТОРЭТИЛ)ФЕНИЛ-6H-ПИРРОЛО[1,2-a][1,4]БЕНЗОДИАЗЕПИНА
WO2009096667A3 (ko) 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물
IL194094A0 (en) Stable pharmacuetical compositions of 2-aza-bicyclol[3.3.0]-octane-3-carboxylic acid derivatives
WO2013124700A3 (en) Composition based on silybum marianum seed oil and process for the preparation of the seed oil
WO2010070057A3 (en) Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability